Evogene
EVGN • NASDAQ
Evogene is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Ofer Haviv, with a market cap of $7.1M.
CEOOfer Haviv
Next Earnings
Upcoming earnings announcement for Evogene
Date
Wednesday, May 20, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.27
Revenue Estimate
$350.0K
Earnings History
Past 12 earnings reports for Evogene
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.61Est: -$0.26 | -134.6% | $314.0KEst: $275.0K | +14.2% | — |
| Nov 20, 2025 | Q3 2025 | -$0.31Est: -$0.41 | +24.4% | $312.0KEst: $650.0K | -52.0% | — |
| Aug 19, 2025 | Q2 2025 | -$0.50Est: -$0.63 | +20.6% | $884.0KEst: $930.0K | -4.9% | — |
| May 21, 2025 | Q1 2025 | -$0.38Est: -$0.50 | +24.0% | $2.4MEst: $4.4M | -44.7% | — |
| Mar 6, 2025 | Q4 2024 | $0.06Est: -$0.73 | +108.2% | $1.6MEst: $3.6M | -55.5% | — |
| Nov 21, 2024 | Q3 2024 | -$1.31Est: -$1.01 | -29.7% | $1.8MEst: $2.9M | -37.0% | — |
| Aug 22, 2024 | Q2 2024 | -$1.06Est: -$1.20 | +11.7% | $914.0KEst: $800.0K | +14.2% | — |
| May 23, 2024 | Q1 2024 | -$0.80Est: -$0.90 | +11.1% | $4.2MEst: $3.5M | +19.7% | — |
| Mar 7, 2024 | Q4 2023 | -$1.30Est: -$1.40 | +7.1% | $578.0KEst: $910.0K | -36.5% | — |
| Nov 15, 2023 | Q3 2023 | -$0.80Est: -$1.60 | +50.0% | $3.8MEst: $1.2M | +219.2% | — |
| Aug 17, 2023 | Q2 2023 | -$1.70Est: -$1.70 | 0.0% | $654.0KEst: $880.0K | -25.7% | — |
| May 18, 2023 | Q1 2023 | -$1.50Est: -$1.60 | +6.3% | $641.0KEst: $870.0K | -26.3% | — |